Trifluorothymidine CAS: 70-00-8

CAS NO: 70-00-8
Trifluorothymidine
Chemical Name: Trifluridine
Molecular Formula: C10H11F3N2O5
Formula Weight: 296.2
CAS No.: 70-00-8
Description Review
Description

Trifluorothymidine, also known as TFT or trifluorothymidine-5'-phosphate, is a synthetic nucleoside analog that has been used in the treatment of various cancers. It is a chemical compound with the chemical name 2'-Deoxy-5-(trifluoromethyl)uridine and has the molecular formula C10H11F3N2O5. Its formula weight is 296.20 g/mol, and its CAS number is 70-00-8.

Top ten keywords from Google regarding Trifluorothymidine are:

  1. Antiviral agent
  2. Cancer treatment
  3. Thymidine analog
  4. Nucleoside analog
  5. Herpes simplex virus
  6. Ophthalmology
  7. Keratitis
  8. Topical application
  9. Combination therapy
  10. Resistance

Synonyms for Trifluorothymidine include TFT, trifluridine, and trifluorothymidine phosphate.

Health benefits of Trifluorothymidine:

Trifluorothymidine has been studied extensively for its potential therapeutic applications in various cancers, particularly colon and rectal cancer. As a thymidine analog, it can inhibit DNA synthesis in rapidly dividing cells, thus inhibiting their growth and proliferation. This makes it a potential candidate for cancer therapy.

Trifluorothymidine has also been used as an antiviral agent for the treatment of herpes simplex virus (HSV) infections, particularly in ophthalmology for the treatment of herpetic keratitis.

Potential effects of Trifluorothymidine:

The primary effect of Trifluorothymidine is inhibition of DNA synthesis in rapidly dividing cells, which can lead to cell death. This effect is particularly useful in the treatment of cancer, as cancer cells typically exhibit rapid division and growth. In the case of HSV infections, Trifluorothymidine can inhibit viral replication by incorporating into the viral DNA and disrupting its replication.

Product mechanism:

The mechanism of action of Trifluorothymidine involves incorporation into cellular and viral DNA, where it disrupts DNA synthesis and replication. In cancer cells, this leads to inhibition of cell growth and proliferation, while in HSV-infected cells, it inhibits viral replication.

Safety:

Trifluorothymidine has been tested in preclinical studies and clinical trials, and its safety profile has been well-established. However, like any other drug, there may be some side effects associated with its use. Therefore, it is important to consult a physician before taking this drug.

Side effects:

Some of the common side effects associated with the use of Trifluorothymidine include ocular discomfort, stinging, irritation, and blurred vision. In rare cases, more serious side effects such as corneal epithelial toxicity and bacterial keratitis have been reported.

Dosing information:

The dosing of Trifluorothymidine varies depending on the condition being treated and the individual patient. Therefore, it is important to follow the dosage instructions provided by a healthcare professional. Trifluorothymidine is typically administered topically for the treatment of HSV infections and orally for the treatment of cancer.

Conclusion:

Trifluorothymidine is a promising drug with potential therapeutic applications in various cancers and HSV infections. As a thymidine analog, it can inhibit DNA synthesis in rapidly dividing cells, thus inhibiting their growth and proliferation. While its safety profile has been established, it is important to consult with a healthcare professional before taking this drug

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code